NCT06064006

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	NNC0487-0111	NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
DRUG	Placebo (NNC0487-0111)	Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.

Timeline

• Start date: 2023-09-15
• Primary completion: 2024-11-27
• Completion: 2024-11-27
• First posted: 2023-10-03
• Last updated: 2025-11-19

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study